12:00 AM
 | 
Dec 03, 2001
 |  BioCentury  |  Finance

Analyst picks & changes

Amgen Inc. (AMGN), Thousand Oaks, Calif.

Business: Biopharmaceuticals

Morgan Stanley analyst Douglas Lind lowered his price target to $89 from $97 and decreased his 2002 EPS estimate to $1.49 from $1.58. He said the changes reflect company...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >